Session Title: Vascular Diseases and Diabetic Retinopathy II
Session Date/Time: Friday 12/09/2014 | 11:00-13:00
Paper Time: 12:12
Venue: Boulevard C
First Author: : T.Papathomas UK
Co Author(s): : L. Makris A. Kamal
Macular oedema (MO) secondary to venous occlusions can be treated with various modalities and recently dexamethasone intravitreal implant 0.7 mg (Ozurdex) has been approved by NICE in UK. We present our series of patients treated with Ozurdex for macular oedema secondary to retinal vein occlusions. The purpose of our study was to evaluate the outcomes, efficacy and safety of intravitreal Ozurdex implant.
A tertiary referral center in Liverpool.
Retrospective study of all eyes that received Ozurdex implant for MO due to retinal vein occlusion with 1 year follow-up. Ninty-six eyes were eligible to enter the study. Sixty-six eyes had branch retinal vein occlusion (BRVO), 30 eyes had central retinal vein occlusion (CRVO). Best Corrected Visual Acuity (BCVA) using Logmar charts and Central Foveal Thickness (CFT) with OCT were evaluated at 2 weeks and then at 2-monthly appointments following the procedure. Safety was evaluated by recording all per-operative as well as post-operative complications, implant induced ocular hypertension and cataract progression.
At 1 year follow-up mean BCVA in BRVO improved from 0.50 to 0.44 and in CRVO from 0.85 to 0.60. Mean CFT improved from 426.79µ to 302.28µ in BRVO and from 587µ to 316µ in CRVO. No per-operative complications were noted. Twenty-nine (30.2%) eyes from both groups had increased intraocular pressure mostly responsive to topical antiglaucoma therapy. One eye required antiglaucoma surgery. Cataract surgery was required in 26 eyes (34.6% of phakic eyes). One eye developed endophthalmitis.
Dexamethasone intravitreal implant 0.7 mg (Ozurdex) can be used as an effective and safe option to maintain visual and anatomic success in retinal vein occlusions with minimal and reversible complications.